Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-613-9 | CAS number: 144-02-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1987
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: study meets generally accepted scientific principles, however focused on limited parameters, acceptable for assessment of hepatic and renal toxicity
Data source
Reference
- Reference Type:
- publication
- Title:
- The Chronic Hepatic or Renal Toxicity of Di(2-ethylhexyl) Phthalate, Acetaminophen, Sodium Barbital, and Phenobarbital in Male B6C3Fl Mice: Autoradiographic, Immunohistochemical, and Biochemical Evidence for Levels of DNA Synthesis Not Associated with...
- Author:
- WARD J. M., HAGIWARA A., ANDERSON L. M., LINDSEY K., DIWAN B. A.
- Year:
- 1 988
- Bibliographic source:
- Toxicology and Applied Pharmacology Vol.96, Pg.494, 1988
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The hypothesis that carcinogenesis or tumor promotion by xenobiotics may result at least in part from increased cell turnover elicited by the chronic cytotoxicity of the chemicals was tested.
- Principle of test:
384 mice were randomized into seven groups of 48 mice each (group 2-7) or 96 mice (group 1) with equal group mean body weights. Animals were maintained on diets containing DEHP at 12.000 or 6000 ppm, ACT at 10,000 or 5000 ppm, or BBS at 1000 ppm, water with PB at 500 ppm, or no test chemical for up to 40 weeks. Twelve mice from each group were killed at 2, 8, 24, and 40 weeks.
- Short description of test conditions:
Mice were housed five per polycarbonate cage in filtered racks, and fed Purina 50 10 autoclavable rodent meal and acidified water adlibitum. Mice were maintained at a temperature of 20 to 22°C and a relative humidity of 50 + 10% with 12 changes ofroom air per hour. Body weights were measured monthly or weekly.
- Parameters analysed / observed:
liver and kidney weights, Thymidine kinase levels in liver and kidneys, levels of hepatic and renal DNA synthesis (by tritiated thymidine autoradiography or BrdU immunohistochemistry) and histopathologic evaluation. - GLP compliance:
- no
Test material
- Reference substance name:
- Barbital sodium
- EC Number:
- 205-613-9
- EC Name:
- Barbital sodium
- Cas Number:
- 144-02-5
- Molecular formula:
- C8H11N2O3.Na
- IUPAC Name:
- sodium 5,5-diethyl-4,6-dioxo-1,4,5,6-tetrahydropyrimidin-2-olate
- Test material form:
- not specified
- Details on test material:
- Sodium barbital purchased from Sigma Chemical Co., St. Louis, MO
Constituent 1
- Specific details on test material used for the study:
- Sodium barbital (BBS) (Sigma Chemical Co., St. Louis, MO), Di(2-ethylhexyl) phthalate (DEHP) (Aldrich Chemical Co.. Inc.. Milwaukee, WI), and acetaminophen (ACT) (Aldrich Chemical Co.) were prepared at designated concentrations for dietary administration by mechanical mixing with feed. phenobarbital (PB)(Sigma Chemical Co.) was dissolved in drinking water for administration.
Test animals
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- test animals:
Four hundred male B6C3Fl mice. 4 weeks of age, were obtained from the NC1 Animal Genetics and Production Branch, Frederick, Maryland.
environmental conditions:
Mice were housed five per polycarbonate cage in filtered racks, and fed Purina 50 10 autoclavable rodent meal and acidified water adlibitum. Mice were maintained at a temperature of 20 to 22°C and a relative humidity of 50 + 10% with 12 changes ofroom air per hour. Body weights were measured monthly or weekly.
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Test chemicals were prepared at designated concentrations for dietary administration by mechanical mixing with feed.
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 2, 8, 24, and 40 weeks
- Frequency of treatment:
- daily
Doses / concentrations
- Dose / conc.:
- 1 000 ppm
- Remarks:
- with diet
- No. of animals per sex per dose:
- 12 male mice per duration of treatment (with diet containing 1000 ppm sodium barbital)
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale:
Doses were based on previous studies of carcinogenicity. tumor promotion, and toxicity (Ward et al., 1986: Hagiwara and Ward, 1986).
- Principle of test:
384 mice were randomized into seven groups of 48 mice each (group 2-7) or 96 mice (group 1) with equal group mean body weights. Animals were
maintained on diets containing DEHP at 12.000 or 6000 ppm, ACT at 10,000 or 5000 ppm, or BBS at 1000 ppm, water with PB at 500 ppm, or no test chemical for up to 40 weeks. Twelve mice from each group were killed at 2, 8, 24, and 40 weeks.
- Short description of test conditions:
Mice were housed five per polycarbonate cage in filtered racks, and fed Purina 50 10 autoclavable rodent meal and acidified water adlibitum. Mice were maintained at a temperature of 20 to 22°C and a relative humidity of 50 + 10% with 12 changes ofroom air per hour. Body weights were measured monthly or weekly.
- Parameters analysed / observed:
At each termination, six mice from each group were used for measuring liver and kidney weights, and for evaluation of Thymidine kinase levels in liver and kidneys. Another six mice were used for evaluation of levels of hepatic and renal DNA synthesis (by tritiated thymidine autoradiography or BrdU immunohistochemistry) and for histopathologic evaluation.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Not specified
DETAILED CLINICAL OBSERVATIONS: Not specified
BODY WEIGHT: Yes
- Time schedule for examinations: monthly or weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No
OTHER:
Evaluation of liver and kidney weights, histopathology, and thymidine kinase (TK) activity in liver and kidney and levels of DNA synthesis, measured by tritiated thymidine ([3H]T) autoradiography or bromodeoxyuridine (BrdU) immunohistochemistry. - Sacrifice and pathology:
- SACRIFICE: Not specified
HISTOPATHOLOGY: Yes
The liver, kidneys, and small intestine were fixed in 10% buffered formalin. Deparaffinized slides were coated with Kodak NTB-3 nuclear track emulsion (Eastman-Kodak Co.. Rochester, NY), exposed for 4 weeks in a light tight box with a drying agent at 4°C. and developed with Kodak D19. Slides were stained with hematoxylin and eosin. The number of labeled nuclei per thousand hepatocytes or renal tubular cells or number per unit area (mm*) were counted in random areas of each organ for each animal. Four to eight high-power (25 X) fields were generally evaluated per tissue. These slides were also examined histopathologically for lesions.
Results and discussion
Results of examinations
- Clinical signs:
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- Sodium barbital did not exhibited severe toxicity as measured by survival.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Sodium barbital did not exhibited severe toxicity as measured by body weight maintenance.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Cell turnover:
Sodium barbital caused both increased hepatocyte labeling indices and thymidine kinase activity in liver at 2 weeks, and elevated TK levels only in the kidney at this time. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Sodium barbital caused significant increases in liver-to-body weight ratios (Histologically, centrilobular cytomegaly was noted). Kidney weights were not
changed. - Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Centrilobular cytomegaly was noted after Sodium barbital treatment. Kidney weights were not changed.
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
- Dose descriptor:
- LOEL
- Effect level:
- 1 000 ppm
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 33 600 mg/kg bw (total dose)
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- not specified
Any other information on results incl. tables
Liver-to-body weight ratios (%) in male B6F3C1 mice fed sodium barbital for up to 40 weeks
Treatment (ppm) | experimental week 2 | experimental week 8 | experimental week 24 | experimental week 40 |
Sodium barbital 1000 | 4.64 ± 0.18 | 4.98 ± 0.13 | 4.89 ± 0.09 | 4.97 ± 0.08 |
control | 4.20 ± 0.04 | 3.97 ± 0.30 | 4.25 ± 0.06 | 3.71 ± 0.08 |
Renal weights (% of body) in male B6F3C1 mice fed sodium barbital for up to 40 weeks
Treatment (ppm) | experimental week 2 | experimental week 8 | experimental week 24 | experimental week 40 |
Sodium barbital 1000 | 1.42 ± 0.02 | 1.39 ± 0.04 | 1.42 ± 0.04 | 1.39 ± 0.04 |
control | 1.38 ± 0.02 | 1.47 ± 0.12 | 1.48 ± 0.04 | 1.45 ± 0.04 |
Applicant's summary and conclusion
- Conclusions:
- Sodium barbital did not exhibited severe toxicity as measured by survival or body weight maintenance, but caused significant increases in liver-to-body weight ratios in male mice. Histologically, centrilobular cytomegaly was noted after sodium barbital treatment. Kidney weights were not changed.
- Executive summary:
The hypothesis that carcinogenesis or tumor promotion by xenobiotics may result at least in part from increased cell turnover elicited by the chronic cytotoxicity of the chemicals was tested. 384 male mice were randomized into seven groups of 48 mice each (group 2-7) or 96 mice (group 1) with equal group mean body weights. Animals were maintained on diets containing DEHP at 12.000 or 6000 ppm, ACT at 10,000 or 5000 ppm, or Sodium barbital at 1000 ppm, water with PB at 500 ppm, or no test chemical for up to 40 weeks. Twelve mice from each group were killed at 2, 8, 24, and 40 weeks. Body weights were measured monthly or weekly. At each termination, six mice from each group were used for measuring liver and kidney weights, and for evaluation of thymidine kinase (TK) levels in liver and kidneys. Another six mice were used for evaluation of levels of hepatic and renal DNA synthesis (by tritiated thymidine autoradiography or BrdU immunohistochemistry) and for histopathologic evaluation.
Sodium barbital did not exhibited severe toxicity as measured by survival or body weight maintenance, but caused significant increases in liver-to-body weight ratios in male mice. Histologically, centrilobular cytomegaly was noted after sodium barbital treatment. Sodium barbital caused both increased hepatocyte labeling indices and TK activity in liver at 2 weeks, and elevated TK levels only in the kidney at this time. Kidney weights were not changed. There were no other major effects on these measures of cell turnover.
The results of this study confirm that increased cell turnover is a clear and expected consequence of high toxicity, but provide no evidence that this phenomenon is a necessary mechanistic component of carcinogenesis or tumor promotion by nongenotoxic carcinogens.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.